SRC and ovarian carcinoma: Despite promising preclinical studies which highlight the potential to target SRC in ovarian cancer, and provide a clear rationale for this clinical trial, results showed no benefit to progression free survival (PFS) when combining saracatinib (AZD0530) with weekly paclitaxel in this patient population [18].